Table 2.
Results of multi-dose growth inhibition assay (GI50, μM).
| Cell line | 12a | 12b | 12c | 17t | 17u | |
|---|---|---|---|---|---|---|
| Leukemia | CCRF-CEM | 2.36 | 2.96 | 0.429 | 0.341 | 0.484 |
| HL-60 (TB) | 1.77 | 1.42 | 0.346 | 0.0542 | 0.165 | |
| K-562 | 1.11 | 0.845 | 0.415 | 0.920 | 0.370 | |
| MOLT-4 | 3.56 | 3.95 | 1.86 | 0.202 | 1.42 | |
| RPMI-8226 | nt | 2.79 | 1.03 | 0.347 | 0.772 | |
| Non-small cell lung cancer | A549/ATCC | 5.81 | 3.77 | 1.02 | 2.65 | 1.87 |
| EKVX | 5.18 | 2.83 | 2.41 | 0.734 | 1.00 | |
| HOP-62 | 7.74 | 3.15 | 1.51 | 0.800 | 2.30 | |
| HOP-92 | 11.4 | 2.87 | 1.96 | 21.2 | 13.2 | |
| NCI-H226 | 7.28 | 3.00 | 2.61 | 1.09 | 1.14 | |
| NCI-H23 | 3.38 | 3.37 | 1.09 | 0.840 | 1.39 | |
| NCI-H460 | 3.59 | 1.76 | 0.662 | 0.453 | 0.479 | |
| NCI-H522 | 2.83 | 2.08 | nt | 0.303 | 0.459 | |
| Colon cancer | COLO 205 | 1.84 | 1.68 | 0.917 | 0.343 | 0.797 |
| HCC-2998 | 6.45 | 0.487 | nt | 1.25 | 0.984 | |
| HCT-116 | 3.20 | 1.98 | 0.663 | 0.430 | 0.509 | |
| HCT-15 | 3.77 | 2.13 | 1.04 | 0.586 | 0.987 | |
| HT29 | 2.31 | 1.94 | 0.527 | 0.367 | 0.376 | |
| KM12 | 2.94 | 1.69 | 0.739 | 0.499 | 0.533 | |
| SW-620 | 3.30 | 1.99 | 0.705 | 0.541 | 0.605 | |
| CNS cancer | SF-268 | 10.9 | 2.90 | 1.83 | 2.31 | 0.778 |
| SF-295 | 3.14 | 1.40 | 0.625 | 0.350 | 0.415 | |
| SF539 | 2.05 | 2.05 | 0.819 | 0.445 | 0.444 | |
| SNB-19 | 5.69 | 3.18 | 2.00 | 0.586 | 1.41 | |
| SNB75 | 3.18 | 1.84 | 2.07 | 0.245 | 1.22 | |
| U251 | 4.13 | 2.14 | 0.887 | 0.501 | 0.663 | |
| Melanoma | LOX IMVI | 7.65 | 4.33 | 3.27 | 3.75 | 4.21 |
| MALME-3M | 7.59 | 2.68 | 1.21 | 1.60 | nt | |
| M14 | 2.35 | 1.71 | 0.482 | 0.429 | 0.698 | |
| MDA-MB-435 | 0.660 | 0.492 | 0.231 | nt | 0.234 | |
| SK-MEL-2 | 4.75 | 2.75 | nt | 1.40 | 0.678 | |
| SK-MEL-28 | 5.24 | 2.88 | 0.839 | 2.51 | nt | |
| SK-MEL-5 | 1.01 | 0.373 | 0.435 | 0.383 | 0.367 | |
| UACC-257 | 17.0 | 15.1 | nt | 14.3 | 38.7 | |
| UACC-62 | 3.77 | 2.52 | 0.782 | 0.632 | 0.388 | |
| Ovarian cancer | IGROV1 | 4.37 | 3.29 | 1023 | 0.917 | 0.352 |
| OVCAR-3 | 2.18 | 1.30 | 0.349 | 0.353 | 0.294 | |
| OVCAR-4 | 11.4 | 2.77 | nt | 1.84 | 2.37 | |
| OVCAR-5 | 8.20 | 2.74 | 2.92 | 3.52 | 4.02 | |
| OVCAR-8 | 7.49 | 3.89 | nt | 1.06 | 56.0 | |
| NCI/ADR-RES | 2.79 | 2.24 | 0.400 | nt | 0.719 | |
| SK-OV-3 | 2.79 | 2.30 | 1.41 | 0.744 | 0.539 | |
| Renal cancer | 786–0 | 4.00 | 2.32 | 1.76 | 1.43 | 0.937 |
| A498 | 5.56 | 3.61 | 1.70 | 2.70 | 0.880 | |
| ACHN | 13.5 | 4.75 | 3.36 | 3.70 | 9.86 | |
| CAKI-1 | 8.92 | 0.263 | 1.34 | 0.648 | 0.637 | |
| RXF 393 | nt | 1.71 | 0.444 | 3.02 | 0.425 | |
| SN12C | 9.63 | 3.96 | 2.96 | 0.635 | 1.55 | |
| TK-10 | 25.8 | 5.51 | 2.67 | 3.15 | 26.7 | |
| UO-31 | 9.62 | 3.57 | 1.85 | 3.53 | 1.63 | |
| Prostate cancer | PC-3 | 3.97 | 3.15 | 0.684 | 0.628 | 0.832 |
| DU-145 | 3.66 | 2.16 | 0.935 | 0.477 | 1.28 | |
| Breast cancer | MCF7 | 3.48 | 1.74 | 0.569 | 0.450 | 0.401 |
| MDA-MB-231 | 7.26 | 2.48 | 2.19 | 0.596 | 1.41 | |
| HS 578T | 1.94 | 2.04 | 0.624 | 0.375 | 0.362 | |
| BT-549 | 4.88 | 3.19 | 1.41 | 9.47 | 0.816 | |
| T-47D | 4.20 | 3.36 | 1.57 | 0.857 | 19.9 | |
| MDA-MB-468 | 3.12 | 1.17 | 0.279 | nt | 0.377 |
nt = not tested.
GI50 = Growth inhibition of 50%; [(Ti−Tz)/(C−Tz)] × 100 = 50 where Tz = absorbance at t = 0, Ti = absorbance at t = 48 h, C = absorbance of control at t = 48 h.